Fred A. Middleton Buys 87,744 Shares of CalciMedica, Inc. (NASDAQ:CALC) Stock

CalciMedica, Inc. (NASDAQ:CALC) Director Fred A. Middleton purchased 87,744 shares of CalciMedica stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average price of $3.75 per share, with a total value of $329,040.00. Following the transaction, the director now owns 814,300 shares of the company’s stock, valued at $3,053,625. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

CalciMedica Trading Down 1.1 %

Shares of NASDAQ:CALC opened at $3.50 on Thursday. The company has a 50-day moving average price of $4.23 and a two-hundred day moving average price of $4.63. CalciMedica, Inc. has a twelve month low of $2.68 and a twelve month high of $8.38.

CalciMedica (NASDAQ:CALC) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.03. As a group, sell-side analysts anticipate that CalciMedica, Inc. will post -2.21 EPS for the current fiscal year.

Hedge Funds Weigh In On CalciMedica

An institutional investor recently raised its position in CalciMedica stock. Atria Investments Inc increased its stake in shares of CalciMedica, Inc. (NASDAQ:CALC) by 136.5% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 26,503 shares of the company’s stock after purchasing an additional 15,296 shares during the period. Atria Investments Inc owned 0.25% of CalciMedica worth $117,000 as of its most recent SEC filing.

Analysts Set New Price Targets

CALC has been the subject of a number of research reports. HC Wainwright reduced their target price on shares of CalciMedica from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Monday. Oppenheimer upped their price objective on CalciMedica from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday, July 10th.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.